Takayasu Arteritis Clinical Trial
Official title:
Comparison of the Efficacy of Mycophenolate Mofetil Combined With Methotrexate and Cyclophosphamide for the Treatment of Takayasu's Arteritis
Takayasu's arteritis(TAK) is a rare systemic vasculitis which can cause ischemia or inflammation of the involved organs and increase the overall mortality rate.The traditional treatment of TAK is primarily empirical. The most commonly used drugs for treating active TAK are glucocorticosteroids(GC) and immunosuppressants. However, the genital toxicity of CYC has limited its long term use. In a pilot study carried out by the principal investigator of this study has shown that mycophenolate mofetil(MMF) combined with MTX is effective and with few adverse effects. The purpose of this prospective open-label study is to compare the efficacy and safety of GC+MMF+MTX with GC+CYC followed by GC+AZA for the treatment of active TAK. 150 patients with active TAK will be recruited and randomized in a 2:1 ratio to GC+MMF+MTX group and C+CYC and AZA group. Patients were followed for 52 weeks for efficacy and safety assessment.
Takayasu's arteritis(TAK) is a rare systemic vasculitis which mainly involves aorta and its major branches. However,it is more prevalent in countries and areas along the silk road.Young women at child-bearing age is the most prevalent population.It can cause ischemia or inflammation of the involved organs and increase the overall mortality rate.Although it may be lethal in some patients,it is not well studied due to the rareness of the disease.The traditional treatment of TAK is primarily empirical. The most commonly used drugs for treating active TAK are glucocorticosteroids(GC) and immunosuppressants including cyclophosphamide(CYC), methotrexate(MTX) and azathioprine(AZA) etc. However,no of these drugs have been well studied. In addition, the genital toxicity of CYC, the first line medication for active TAK, has become the major limitation for its long term use for a chronic disease like TAK. Therefore, new immunosuppressants with less toxicity,especially with much less genital toxicity and low malignancy risk is essentially necessary. In a pilot study carried out by the principal investigator of this study has shown that mycophenolate mofetil(MMF) combined with MTX is effective and with few adverse effects. The purpose of this prospective open-label study is to compare the efficacy and safety of GC+MMF+MTX with GC+CYC followed by GC+AZA for the treatment of active TAK. 150 patients with active TAK will be recruited and randomized in a 2:1 ratio to GC+MMF+MTX group and C+CYC and AZA group. Patients were followed for 52 weeks to assess the efficacy and safety. ;
Status | Clinical Trial | Phase | |
---|---|---|---|
Not yet recruiting |
NCT04564001 -
Multicentre, Randomized, Prospective Trial Evaluating the Efficacy and Safety of Infliximab to Tocilizumab in Refractory or Relapsing Takayasu Arteritis
|
Phase 2 | |
Terminated |
NCT04882072 -
A Study of Ustekinumab in Participants With Takayasu Arteritis (TAK)
|
Phase 3 | |
Completed |
NCT03750929 -
Aerobic Capacity and Strength Exercise in Takayasu's Arteritis
|
N/A | |
Recruiting |
NCT04137614 -
Drug-coated Balloon for Takayasu Arteritis Associated Renal Artery Stenosis
|
N/A | |
Recruiting |
NCT02967068 -
VCRC Tissue Repository
|
||
Recruiting |
NCT05102448 -
Comparison of Tofacitinib and Methotrexate in Takayasu's Arteritis
|
Phase 4 | |
Recruiting |
NCT03893136 -
The Registry Study of Takayasu Arteritis in East China
|
||
Active, not recruiting |
NCT00006055 -
Autologous Peripheral Blood Stem Cell Transplantation in Patients With Life Threatening Autoimmune Diseases
|
N/A | |
Recruiting |
NCT04299971 -
Efficiency of Methotrexate and Tofacitinib in Mild and Moderate Patients
|
Phase 4 | |
Recruiting |
NCT04300686 -
A Pilot Study in Severe Patients With Takayasu Arteritis.
|
Phase 4 | |
Recruiting |
NCT03192878 -
Infliximab Biosimilar in Takayasu's Arteritis
|
N/A | |
Active, not recruiting |
NCT04071691 -
PET Imaging of Giant Cell and Takayasu Arteritis
|
||
Recruiting |
NCT05904301 -
Armenian NAtionwide REGistry of Systemic Autoimmune and Autoinflammatory Diseases
|
||
Completed |
NCT02101333 -
Efficacy and Tolerance of Tocilizumab In Takayasu Arteritis
|
Phase 3 | |
Not yet recruiting |
NCT03550781 -
Anti-inflammatory Treatment for Inactive Takayasu Arteritis
|
Phase 2/Phase 3 | |
Active, not recruiting |
NCT05168475 -
Biologics in Refractory Vasculitis
|
Phase 2 | |
Completed |
NCT03956394 -
Takayasu Arteritis Activity Evaluation by Ultrafast Ultrasound Imaging
|
N/A | |
Recruiting |
NCT05151848 -
Comparison of Adalimumab and Tofacitinib in the Treatment of Active Takayasu Arteritis
|
Phase 4 | |
Completed |
NCT03430388 -
Yellow Fever Vaccine in Patients With Rheumatic Diseases
|
N/A | |
Completed |
NCT02925351 -
Fluorine F 18 Clofarabine PET/CT in Imaging Patients With Autoimmune or Inflammatory Diseases
|
Early Phase 1 |